Income statement
USD
Annual
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 24M | 43M | 43M | 17M | 3M |
| Gross Profit | 4M | 27M | 27M | 13M | 2M |
| Operating Income | -47M | -20M | -20M | -12M | -2M |
| EBITDA | -84M | -12M | -11M | -8M | -1M |
| Net Income | -86M | -86M | -15M | -6M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Predictive Discovery Limited (PREDQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -43.8%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue -43.8%, EPS 0.0%, free cash flow -1892.3% with operating margin -190.9% and ROIC -63.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PREDQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PREDQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PREDQ Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PREDQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.6M
-84.4% YoY
FY Net Income
-$6.2M
-1.7% YoY
Free Cash Flow
$366.1K
+132.1% YoY
Revenue Growth
-43.8%
EPS Growth
+0.0%
Gross Margin
15.8%
Net Margin
-351.4%
Income statement
USD
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 24M | 43M | 43M | 17M | 3M |
| Gross Profit | 4M | 27M | 27M | 13M | 2M |
| Operating Income | -47M | -20M | -20M | -12M | -2M |
| EBITDA | -84M | -12M | -11M | -8M | -1M |
| Net Income | -86M | -86M | -15M | -6M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Cash & Equivalents | 331K | 331K | 2M | 968K | 5K |
| Total Assets | 84M | 84M | 144M | 104M | 40M |
| Total Liabilities | 29M | 29M | 31M | 23M | 100K |
| Shareholder Equity | 55M | 55M | 113M | 81M | 40M |
| Total Debt | 8M | 8M | 2M | 0 | 0 |
| Net Debt | 8M | 8M | 798K | -968K | -5K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
887K
-3.4% YoY
Capital Expenditures
520K
+74.7% YoY
Free Cash Flow
366K
+132.1% YoY
Key ratios
Gross Margin
15.8%
Operating Margin
-190.9%
Net Margin
-351.4%
ROE
-155.4%
Debt / Equity
0.14x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.